Answers are grounded in this paper and cite their sources.
Examines folate and magnesium supplementation's effects on dolutegravir toxicity in zebrafish, highlighting significant implications for maternal health.
Dolutegravir is a widely used drug for treating human immunodeficiency virus (HIV), but evidence from studies in Botswana and the USA has shown that there is a higher prevalence of infant neural tube defects or pregnancy loss, respectively, in mothers taking this drug when they conceived. Dolutegravir chelates magnesium ions as part of its antiviral activity and is also known to act as an antagonist of folate receptor 1 (FOLR1). Importantly, folate stress and magnesium deficiency are both linked to embryonic malformations, including neural tube defects. The effects of dolutegravir on early embryonic development need to be dissected further to advance clinical strategies that can mitigate potential toxicity.In their study, Cabrera, Gorelick and colleagues determine whether folate and/or magnesium supplementation can prevent dolutegravir toxicity in developing zebrafish. First, they exposed zebrafish embryos to dolutegravir at 2-4 h post fertilisation, which mimics the periconceptional period in humans that has been linked to dolutegravir toxicity. The authors observed significantly increased mortality and abnormalities in zebrafish embryos exposed to dolutegravir compared to those exposed to vehicle control at 1 day post fertilisation, and this was reversed by co-treatment with folate or magnesium, but not calcium. They then performed an in vitro competitive folate binding assay to determine whether magnesium could prevent dolutegravir antagonism of FOLR1. In the presence of dolutegravir, increasing concentrations of magnesium partially restored folate binding to FOLR1. The authors then used CRISPR-Cas9 to generate second-generation folate receptor mutant zebrafish (MZfolr1) that received reduced levels of maternal folate. MZfolr1 embryos exhibited developmental abnormalities and were more sensitive to dolutegravir-induced mortality than were wild-type embryos. Interestingly, folate co-treatment did not rescue dolutegravir developmental toxicity in MZfolr1 embryos, but magnesium supplementation did partially mitigate the effects. This suggests that dolutegravir-induced magnesium sequestration acts upstream of FOLR1 antagonism.Overall, the authors have depicted a dual mechanism of dolutegravir developmental toxicity by which folate transport is inhibited and magnesium is chelated, which further impairs folate-dependent mechanisms as well as the function of other magnesium-dependent proteins important for development. They reveal that supplementing with both folate and magnesium can overcome this toxicity, which could be a strategy to prevent developmental abnormalities and pregnancy loss in mothers with HIV, especially in countries in which grains are not routinely fortified with folate.
No takes yet. Share an insight, caveat, or question.
Kirsty Hooper (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: